{"gene":"CDC42BPB","run_date":"2026-06-09T22:57:18","timeline":{"discoveries":[{"year":1999,"finding":"CDC42BPB (MRCKβ) was cloned as the human homologue of rat MRCKβ; it encodes a serine/threonine protein kinase that phosphorylates nonmuscle myosin light chain, a prerequisite for activation of actin-myosin contractility, and is expressed broadly across tissues. The gene maps to cytogenetic band 14q32.3.","method":"cDNA cloning, Northern blot analysis, FISH chromosomal mapping","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cloning with functional annotation from rat studies, single lab, multiple methods (Northern blot, FISH); myosin light chain phosphorylation activity inferred from rat MRCKβ characterization referenced in abstract, not directly re-demonstrated in this paper","pmids":["10198171"],"is_preprint":false},{"year":2019,"finding":"CDC42BPB (MRCKβ) functions as a downstream effector of CDC42 in epithelial cells, where it participates in apical membrane morphogenesis, lumen formation, and junction maturation by coordinating cytoskeleton regulation in response to localized CDC42 activation.","method":"Review synthesizing genetic and cell-biological studies in multiple model systems (Drosophila, C. elegans, mammalian epithelial cells)","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — synthesis of multiple experimental studies linking CDC42BPB to CDC42 effector function in epithelial polarity; not a single direct experiment but draws on established genetic epistasis and loss-of-function data across labs","pmids":["31113848"],"is_preprint":false},{"year":2009,"finding":"CDC42BPB kinase activity regulates cation-independent mannose 6-phosphate receptor (CI-M6PR) trafficking in HeLa cells; siRNA knockdown of CDC42BPB was identified in a visual screen as perturbing CI-M6PR membrane trafficking pathways.","method":"High-throughput fluorescence imaging screen using kinase siRNA library and kinase inhibitors in HeLa cells","journal":"Genes to cells","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, high-throughput screen without mechanistic follow-up on CDC42BPB specifically; no direct biochemical validation of the trafficking phenotype","pmids":["19210549"],"is_preprint":false},{"year":2013,"finding":"CDC42BPB (Cdc42bpb) protein is present in the apical plasma membrane of mouse cortical collecting duct cells and undergoes significant abundance changes in response to vasopressin, implicating it as a signal-induced regulator of F-actin dynamics in this context.","method":"Stable isotope-based quantitative protein mass spectrometry combined with surface biotinylation of apical plasma membrane proteins","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative proteomics with surface biotinylation showing vasopressin-regulated changes in apical membrane abundance; single lab but two orthogonal quantitative methods","pmids":["24085853"],"is_preprint":false},{"year":2013,"finding":"CDC42BPB was identified as a novel putative target kinase of the Akt inhibitor GSK690693, detected by chemical affinity profiling using a synthesized AGC kinase-targeting probe in human cancer cell lysates.","method":"Chemical proteomics / kinase affinity profiling using synthesized chemical probe (kinobeads) combined with mass spectrometry in human cancer cells","journal":"Journal of proteome research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single chemical proteomics method; putative target identification without direct enzyme inhibition assay or mutagenesis validation","pmids":["23795919"],"is_preprint":false},{"year":2017,"finding":"CDC42BPB (Cdc42bpb) was identified as a protein kinase that physically interacts with the urea channel UT-A1 in native rat inner medullary collecting duct cells, and in vitro incubation experiments showed that Cdc42bpb was capable of phosphorylating known UT-A1 phosphorylation sites.","method":"Chemical cross-linking, immunoprecipitation, LC-MS/MS, and in vitro kinase assay using UT-A1 peptides","journal":"American journal of physiology. Cell physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP/MS identification of interaction confirmed by in vitro kinase phosphorylation of substrate peptides; single lab, two orthogonal methods","pmids":["29046292"],"is_preprint":false},{"year":2021,"finding":"MRCKβ (CDC42BPB) phosphorylates the E3 ubiquitin ligase Siah2 at Ser6 and Thr279 in H. pylori-infected gastric epithelial cells. This phosphorylation stabilizes Siah2 and promotes its tumorigenic functions; in turn, Siah2 ubiquitinates MRCKβ leading to its proteasomal degradation. Phosphorylation-null Siah2 mutants (S6A and T279A) showed reduced tumorigenicity.","method":"Co-immunoprecipitation followed by mass spectrometry to identify kinase, site-directed mutagenesis of Siah2 phosphorylation sites, western blotting, proteasome inhibitor rescue (MG132), clonogenicity, proliferation, invasion, and anchorage-independent growth assays","journal":"Journal of biomedical science","confidence":"High","confidence_rationale":"Tier 1 / Moderate — Co-IP/MS identification of kinase, mutagenesis of substrate phosphorylation sites with functional phenotypic validation (tumorigenicity assays), proteasomal rescue experiment; multiple orthogonal methods in single lab","pmids":["33536006"],"is_preprint":false},{"year":2020,"finding":"Heterozygous predicted loss-of-function variants in CDC42BPB (frameshift and nonsense), expected to cause haploinsufficiency via nonsense-mediated decay, and missense variants in functionally important protein domains (kinase domain, citron homology domain, coiled-coil regions) are associated with neurodevelopmental disorders including developmental delay, intellectual disability, autism, and structural brain abnormalities. Variants were confirmed de novo in 11/14 individuals.","method":"Whole-exome/genome sequencing with de novo variant confirmation in 14 unrelated individuals; in silico domain mapping of missense variants","journal":"American journal of medical genetics. Part A","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — human genetic evidence across 14 unrelated individuals with de novo confirmation; domain localization provides functional inference but no direct biochemical assay of variant effects","pmids":["32031333"],"is_preprint":false},{"year":2024,"finding":"CDC42BPB kinase phosphorylates AURKA, which in turn upregulates PD-L1 through cMYC in breast cancer cells. CRISPR-Cas9 kinome knockout of CDC42BPB and pharmacological inhibition with BDP5290 synergized with anti-PD-1 to enhance T cell-mediated tumor killing. Anti-PD-1-resistant breast cancer cells showed higher CDC42BPB expression, and its inhibition restored susceptibility to T cell killing.","method":"CRISPR-Cas9 kinome knockout library screen, pharmacological inhibition (BDP5290), in vitro T cell killing assay, in vivo mouse tumor models, mechanistic analysis of AURKA-cMYC-PD-L1 axis","journal":"Molecular therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR screen combined with pharmacological inhibition and in vitro/in vivo validation; AURKA phosphorylation by CDC42BPB stated but the abstract does not detail direct biochemical phosphorylation assay; single lab","pmids":["39086134"],"is_preprint":false},{"year":2026,"finding":"Loss of Cdc42bpb in mice leads to ventral diaphragmatic hernias, heart septal defects, and minor lung epithelial differentiation defects in embryos. Installation of a patient-specific missense variant via CRISPR/Cas9 knock-in resulted in less severe ventral diaphragm defects, establishing CDC42BPB as a genetic cause of congenital diaphragmatic hernia.","method":"Mouse knockout (loss-of-function) and CRISPR/Cas9 patient-variant knock-in; embryonic phenotyping for diaphragm, heart, and lung defects","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo loss-of-function with specific anatomical phenotypic readouts and patient-variant knock-in; preprint, single lab, not yet peer-reviewed","pmids":["42124667"],"is_preprint":true},{"year":2022,"finding":"Heterozygous deletion of Cdc42bpb in mice (Cdc42bpb +/-) did not produce significant differences from wild-type littermates in alcohol-related behavioral tests (loss of righting reflex, light-dark box, two-bottle choice drinking), though mild hyperactivity and some urogenital deformities were observed.","method":"Behavioral battery testing in heterozygous Cdc42bpb knockout mice","journal":"microPublication biology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct in vivo loss-of-function experiment with specific behavioral readouts; negative result for alcohol behaviors is informative; single lab, single method","pmids":["35622514"],"is_preprint":false}],"current_model":"CDC42BPB (MRCKβ) is a serine/threonine protein kinase and downstream effector of CDC42 that phosphorylates nonmuscle myosin light chain to activate actin-myosin contractility, phosphorylates Siah2 (promoting its stability while triggering its own proteasomal degradation via Siah2-mediated ubiquitination), and phosphorylates AURKA to upregulate PD-L1 via cMYC; it regulates actin cytoskeleton dynamics, epithelial polarity, membrane trafficking, and vasopressin-regulated actin remodeling in renal collecting duct cells, and is required for normal diaphragm and heart development in vivo, with loss-of-function and dominant missense variants causing neurodevelopmental disorders and congenital diaphragmatic hernia in humans and mice."},"narrative":{"mechanistic_narrative":"CDC42BPB (MRCKβ) is a broadly expressed serine/threonine protein kinase that acts as a downstream effector of CDC42 to regulate the actin cytoskeleton, epithelial polarity, and membrane morphogenesis [PMID:10198171, PMID:31113848]. Through phosphorylation of nonmuscle myosin light chain it links CDC42 activation to actin-myosin contractility, and in epithelial cells it coordinates apical membrane morphogenesis, lumen formation, and junction maturation in response to localized CDC42 signaling [PMID:10198171, PMID:31113848]. In the renal collecting duct, the kinase localizes to the apical plasma membrane where its abundance changes upon vasopressin stimulation, and it interacts with and phosphorylates the urea channel UT-A1, implicating it in signal-induced F-actin and membrane-transport regulation [PMID:24085853, PMID:29046292]. CDC42BPB also has substrate roles in disease contexts: it phosphorylates the E3 ligase Siah2 at Ser6/Thr279 to stabilize Siah2 and promote tumorigenicity, while Siah2 reciprocally ubiquitinates MRCKβ to drive its proteasomal degradation [PMID:33536006], and it phosphorylates AURKA to upregulate PD-L1 via cMYC, with its loss or inhibition restoring tumor susceptibility to T cell killing [PMID:39086134]. In vivo, loss of Cdc42bpb in mice produces ventral diaphragmatic hernias and heart septal defects, establishing the gene as a genetic cause of congenital diaphragmatic hernia [PMID:42124667]. Heterozygous loss-of-function and de novo missense variants in the kinase, citron homology, and coiled-coil domains cause neurodevelopmental disorders including developmental delay, intellectual disability, and autism [PMID:32031333].","teleology":[{"year":1999,"claim":"Established the molecular identity and core enzymatic activity of the human gene by cloning it as a serine/threonine kinase acting on nonmuscle myosin light chain.","evidence":"cDNA cloning, Northern blot, and FISH mapping of the human MRCKβ homologue","pmids":["10198171"],"confidence":"Medium","gaps":["Myosin light chain phosphorylation inferred from rat ortholog, not directly re-demonstrated","No structural or substrate-site characterization in human protein"]},{"year":2009,"claim":"Addressed whether the kinase participates in intracellular trafficking by implicating it in mannose-6-phosphate receptor membrane transport.","evidence":"High-throughput kinase siRNA/inhibitor fluorescence imaging screen of CI-M6PR trafficking in HeLa cells","pmids":["19210549"],"confidence":"Low","gaps":["Screen hit without mechanistic follow-up specific to CDC42BPB","No biochemical validation of the trafficking phenotype"]},{"year":2013,"claim":"Connected the kinase to physiological signaling by showing its apical membrane abundance in collecting duct cells changes with vasopressin, suggesting a role in signal-induced actin remodeling.","evidence":"Quantitative SILAC mass spectrometry with apical surface biotinylation in mouse cortical collecting duct cells","pmids":["24085853"],"confidence":"Medium","gaps":["Abundance change does not establish a direct kinase substrate in this context","Functional consequence for actin dynamics not directly assayed"]},{"year":2017,"claim":"Identified a tissue-specific substrate by showing the kinase binds and phosphorylates the urea channel UT-A1, linking it to renal transport regulation.","evidence":"Cross-linking, Co-IP/LC-MS/MS, and in vitro kinase assay on UT-A1 peptides in rat inner medullary collecting duct","pmids":["29046292"],"confidence":"Medium","gaps":["Phosphorylation shown on peptides, not validated on full-length UT-A1 in vivo","Functional effect on channel activity not measured"]},{"year":2020,"claim":"Established human disease relevance by linking heterozygous loss-of-function and de novo missense variants to neurodevelopmental disorders.","evidence":"Whole-exome/genome sequencing of 14 unrelated individuals with de novo confirmation and in silico domain mapping","pmids":["32031333"],"confidence":"Medium","gaps":["No direct biochemical assay of variant effects on kinase activity","Mechanism connecting haploinsufficiency to brain phenotype unresolved"]},{"year":2021,"claim":"Revealed a reciprocal kinase-ligase relationship by showing MRCKβ phosphorylates and stabilizes Siah2 while being targeted for degradation by it, defining an oncogenic feedback loop.","evidence":"Co-IP/MS, site-directed mutagenesis (S6A/T279A), MG132 rescue, and tumorigenicity assays in H. pylori-infected gastric epithelial cells","pmids":["33536006"],"confidence":"High","gaps":["Whether this circuit operates outside gastric cancer not addressed","Upstream signals controlling the loop not defined"]},{"year":2024,"claim":"Connected the kinase to tumor immune evasion by showing it phosphorylates AURKA to upregulate PD-L1 via cMYC and modulate anti-PD-1 response.","evidence":"CRISPR-Cas9 kinome screen, BDP5290 inhibition, in vitro T cell killing, and in vivo breast cancer models","pmids":["39086134"],"confidence":"Medium","gaps":["Direct biochemical AURKA phosphorylation assay not detailed","Generality beyond breast cancer not established"]},{"year":2026,"claim":"Established CDC42BPB as a genetic cause of congenital diaphragmatic hernia through in vivo loss-of-function and patient-variant modeling.","evidence":"Mouse knockout and CRISPR/Cas9 patient-variant knock-in with embryonic phenotyping of diaphragm, heart, and lung (preprint)","pmids":["42124667"],"confidence":"Medium","gaps":["Preprint, not yet peer-reviewed","Cellular mechanism linking kinase loss to diaphragm defect not resolved"]},{"year":null,"claim":"The direct in-cell substrate repertoire that mediates the cytoskeletal, developmental, and disease phenotypes, and how CDC42 activation is mechanistically transduced through MRCKβ in each tissue, remain undefined.","evidence":"","pmids":[],"confidence":"Low","gaps":["No unifying mechanistic link between actin regulation and the diverse disease phenotypes","No structural model of substrate recognition","Variant effects on kinase activity not biochemically tested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,5,6,8]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,5,6]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[3]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[9]}],"complexes":[],"partners":["CDC42","SIAH2","AURKA","UT-A1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9Y5S2","full_name":"Serine/threonine-protein kinase MRCK beta","aliases":["CDC42-binding protein kinase beta","CDC42BP-beta","DMPK-like beta","Myotonic dystrophy kinase-related CDC42-binding kinase beta","MRCK beta","Myotonic dystrophy protein kinase-like beta"],"length_aa":1711,"mass_kda":194.3,"function":"Serine/threonine-protein kinase which is an important downstream effector of CDC42 and plays a role in the regulation of cytoskeleton reorganization and cell migration. Regulates actin cytoskeletal reorganization via phosphorylation of PPP1R12C and MYL9/MLC2 (PubMed:21457715, PubMed:21949762). In concert with MYO18A and LURAP1, is involved in modulating lamellar actomyosin retrograde flow that is crucial to cell protrusion and migration (PubMed:18854160). Phosphorylates PPP1R12A (PubMed:21457715). In concert with FAM89B/LRAP25 mediates the targeting of LIMK1 to the lamellipodium resulting in its activation and subsequent phosphorylation of CFL1 which is important for lamellipodial F-actin regulation (By similarity)","subcellular_location":"Cytoplasm; Cell membrane; Cell junction; Cell projection, lamellipodium","url":"https://www.uniprot.org/uniprotkb/Q9Y5S2/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CDC42BPB","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000198752","cell_line_id":"CID001141","localizations":[{"compartment":"membrane","grade":3},{"compartment":"nucleoplasm","grade":1}],"interactors":[{"gene":"FAM89A","stoichiometry":4.0},{"gene":"CDC42","stoichiometry":0.2},{"gene":"CDC42BPA","stoichiometry":0.2},{"gene":"FAM167A","stoichiometry":0.2},{"gene":"HIST1H2BN;HIST1H2BM;HIST1H2BH;HIST2H2BF;HIST1H2BC;HIST1H2BD;HIST1H2BK;H2BFS","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001141","total_profiled":1310},"omim":[{"mim_id":"619841","title":"CHILTON-OKUR-CHUNG NEURODEVELOPMENTAL SYNDROME; CHOCNS","url":"https://www.omim.org/entry/619841"},{"mim_id":"616129","title":"LEUCINE-RICH ADAPTOR PROTEIN 1; LURAP1","url":"https://www.omim.org/entry/616129"},{"mim_id":"614062","title":"CDC42-BINDING PROTEIN KINASE, BETA; CDC42BPB","url":"https://www.omim.org/entry/614062"},{"mim_id":"613991","title":"CDC42-BINDING PROTEIN KINASE, GAMMA; CDC42BPG","url":"https://www.omim.org/entry/613991"},{"mim_id":"610067","title":"MYOSIN XVIIIA; MYO18A","url":"https://www.omim.org/entry/610067"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CDC42BPB"},"hgnc":{"alias_symbol":["MRCKB","KIAA1124"],"prev_symbol":[]},"alphafold":{"accession":"Q9Y5S2","domains":[{"cath_id":"3.30.200.20","chopping":"28-158_362-409","consensus_level":"medium","plddt":89.5778,"start":28,"end":409},{"cath_id":"1.10.510.10","chopping":"172-361","consensus_level":"medium","plddt":92.8325,"start":172,"end":361},{"cath_id":"3.30.60.20","chopping":"1023-1086","consensus_level":"medium","plddt":84.5173,"start":1023,"end":1086},{"cath_id":"2.30.29.30","chopping":"1094-1223","consensus_level":"medium","plddt":84.8665,"start":1094,"end":1223}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y5S2","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y5S2-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y5S2-F1-predicted_aligned_error_v6.png","plddt_mean":75.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CDC42BPB","jax_strain_url":"https://www.jax.org/strain/search?query=CDC42BPB"},"sequence":{"accession":"Q9Y5S2","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9Y5S2.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9Y5S2/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y5S2"}},"corpus_meta":[{"pmid":"18778695","id":"PMC_18778695","title":"Molecular profiles of schizophrenia in the CNS at different stages of illness.","date":"2008","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/18778695","citation_count":174,"is_preprint":false},{"pmid":"29998287","id":"PMC_29998287","title":"DNA Methylation Signatures of Depressive Symptoms in Middle-aged and Elderly Persons: Meta-analysis of Multiethnic Epigenome-wide Studies.","date":"2018","source":"JAMA psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/29998287","citation_count":87,"is_preprint":false},{"pmid":"31113848","id":"PMC_31113848","title":"Regulation of Cdc42 and its effectors in epithelial morphogenesis.","date":"2019","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/31113848","citation_count":86,"is_preprint":false},{"pmid":"24085853","id":"PMC_24085853","title":"Quantitative apical membrane proteomics reveals vasopressin-induced actin dynamics in collecting duct cells.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24085853","citation_count":60,"is_preprint":false},{"pmid":"21352556","id":"PMC_21352556","title":"A Boolean-based systems biology approach to predict novel genes associated with cancer: Application to colorectal cancer.","date":"2011","source":"BMC systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/21352556","citation_count":48,"is_preprint":false},{"pmid":"28193625","id":"PMC_28193625","title":"Deep Sequencing of Urinary RNAs for Bladder Cancer Molecular Diagnostics.","date":"2017","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/28193625","citation_count":28,"is_preprint":false},{"pmid":"23795919","id":"PMC_23795919","title":"Characterization of a chemical affinity probe targeting Akt kinases.","date":"2013","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/23795919","citation_count":28,"is_preprint":false},{"pmid":"39696436","id":"PMC_39696436","title":"Epigenome-wide association studies identify novel DNA methylation sites associated with PTSD: a meta-analysis of 23 military and civilian cohorts.","date":"2024","source":"Genome medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39696436","citation_count":23,"is_preprint":false},{"pmid":"21471979","id":"PMC_21471979","title":"Common variants on 14q32 and 13q12 are associated with DLBCL susceptibility.","date":"2011","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21471979","citation_count":23,"is_preprint":false},{"pmid":"29046292","id":"PMC_29046292","title":"Identification of UT-A1- and AQP2-interacting proteins in rat inner medullary collecting duct.","date":"2017","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29046292","citation_count":17,"is_preprint":false},{"pmid":"19210549","id":"PMC_19210549","title":"Visual screening and analysis for kinase-regulated membrane trafficking pathways that are involved in extensive beta-amyloid secretion.","date":"2009","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/19210549","citation_count":14,"is_preprint":false},{"pmid":"10198171","id":"PMC_10198171","title":"Cloning and chromosomal localization of human Cdc42-binding protein kinase beta.","date":"1999","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/10198171","citation_count":14,"is_preprint":false},{"pmid":"32031333","id":"PMC_32031333","title":"De novo heterozygous missense and loss-of-function variants in CDC42BPB are associated with a neurodevelopmental phenotype.","date":"2020","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/32031333","citation_count":13,"is_preprint":false},{"pmid":"33766467","id":"PMC_33766467","title":"Bladder cancer risk stratification using a urinary mRNA biomarker panel - A path towards cystoscopy triaging.","date":"2021","source":"Urologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33766467","citation_count":13,"is_preprint":false},{"pmid":"29197136","id":"PMC_29197136","title":"Properties of human genes guided by their enrichment in rare and common variants.","date":"2017","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/29197136","citation_count":12,"is_preprint":false},{"pmid":"35319816","id":"PMC_35319816","title":"A novel fusion between CDC42BPB and ALK in a patient with quadruple wild-type gastrointestinal stromal tumor.","date":"2022","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35319816","citation_count":11,"is_preprint":false},{"pmid":"36233195","id":"PMC_36233195","title":"Candidate Modifier Genes for the Penetrance of Leber's Hereditary Optic Neuropathy.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36233195","citation_count":11,"is_preprint":false},{"pmid":"33536006","id":"PMC_33536006","title":"Helicobacter pylori-induced gastric cancer is orchestrated by MRCKβ-mediated Siah2 phosphorylation.","date":"2021","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/33536006","citation_count":11,"is_preprint":false},{"pmid":"38521921","id":"PMC_38521921","title":"Integrative multi-omics analysis identifies genetically supported druggable targets and immune cell specificity for myasthenia gravis.","date":"2024","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38521921","citation_count":9,"is_preprint":false},{"pmid":"38449057","id":"PMC_38449057","title":"Tetramethylpyrazine alleviates hypoxia-induced proliferation, migration, and inflammatory response of fibroblast-like synoviocytes via inhibiting the HIF-1α- circCDC42BPB pathway.","date":"2024","source":"Advances in rheumatology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/38449057","citation_count":8,"is_preprint":false},{"pmid":"32174956","id":"PMC_32174956","title":"Systems Genetics of Optic Nerve Axon Necrosis During Glaucoma.","date":"2020","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32174956","citation_count":8,"is_preprint":false},{"pmid":"38659056","id":"PMC_38659056","title":"Mendelian randomization and colocalization analysis reveal novel drug targets for myasthenia gravis.","date":"2024","source":"Human genomics","url":"https://pubmed.ncbi.nlm.nih.gov/38659056","citation_count":7,"is_preprint":false},{"pmid":"39329449","id":"PMC_39329449","title":"DNA methylation as a new tool for the differential diagnosis between T-LBL and lymphocyte-rich thymoma.","date":"2024","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/39329449","citation_count":6,"is_preprint":false},{"pmid":"24911953","id":"PMC_24911953","title":"Protein kinases paralleling late-phase LTP formation in dorsal hippocampus in the rat.","date":"2014","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/24911953","citation_count":5,"is_preprint":false},{"pmid":"39086134","id":"PMC_39086134","title":"Tumor-intrinsic CDC42BPB confers resistance to anti-PD-1 immune checkpoint blockade in breast cancer.","date":"2024","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/39086134","citation_count":4,"is_preprint":false},{"pmid":"39024358","id":"PMC_39024358","title":"Bayesian mapping of protein kinases to vasopressin-regulated phosphorylation sites in renal collecting duct.","date":"2024","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/39024358","citation_count":3,"is_preprint":false},{"pmid":"39072012","id":"PMC_39072012","title":"Epigenome-wide association studies identify novel DNA methylation sites associated with PTSD: A meta-analysis of 23 military and civilian cohorts.","date":"2024","source":"medRxiv : the preprint server for health sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39072012","citation_count":3,"is_preprint":false},{"pmid":"40133893","id":"PMC_40133893","title":"A case of quadruple wild-type gastrointestinal stromal tumor with CDC42BPB::NTRK3 fusion and abundant lymphoid infiltration.","date":"2025","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/40133893","citation_count":2,"is_preprint":false},{"pmid":"41405980","id":"PMC_41405980","title":"Recurrence in Patients With Lymph Node-Negative Pancreatic Neuroendocrine Tumors.","date":"2026","source":"JAMA surgery","url":"https://pubmed.ncbi.nlm.nih.gov/41405980","citation_count":2,"is_preprint":false},{"pmid":"37705935","id":"PMC_37705935","title":"A Case Report of Cardiofaciocutaneous Syndrome with MAP2K1 Pathogenic Variant.","date":"2023","source":"Pharmacogenomics and personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37705935","citation_count":2,"is_preprint":false},{"pmid":"32043305","id":"PMC_32043305","title":"Sequence variant in the CDC42BPB gene is potentially associated with Mullerian duct anomalies.","date":"2020","source":"The journal of obstetrics and gynaecology research","url":"https://pubmed.ncbi.nlm.nih.gov/32043305","citation_count":1,"is_preprint":false},{"pmid":"42124667","id":"PMC_42124667","title":"Modeling patient variants of Cnot1 and Cdc42bpb results in distinct forms of congenital diaphragmatic hernia in mice.","date":"2026","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/42124667","citation_count":0,"is_preprint":false},{"pmid":"35622514","id":"PMC_35622514","title":"Heterozygous deletion of Cdc42bpb does not alter ethanol behaviors in mice.","date":"2022","source":"microPublication biology","url":"https://pubmed.ncbi.nlm.nih.gov/35622514","citation_count":0,"is_preprint":false},{"pmid":"41616292","id":"PMC_41616292","title":"Cell division cycle 42 binding protein beta as a plasma-based biomarker for cerebral cavernous malformations.","date":"2026","source":"Journal of neurosurgery. Pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/41616292","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":21222,"output_tokens":2988,"usd":0.054243,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":10426,"output_tokens":2856,"usd":0.061765,"stage2_stop_reason":"end_turn"},"total_usd":0.116008,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"CDC42BPB (MRCKβ) was cloned as the human homologue of rat MRCKβ; it encodes a serine/threonine protein kinase that phosphorylates nonmuscle myosin light chain, a prerequisite for activation of actin-myosin contractility, and is expressed broadly across tissues. The gene maps to cytogenetic band 14q32.3.\",\n      \"method\": \"cDNA cloning, Northern blot analysis, FISH chromosomal mapping\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cloning with functional annotation from rat studies, single lab, multiple methods (Northern blot, FISH); myosin light chain phosphorylation activity inferred from rat MRCKβ characterization referenced in abstract, not directly re-demonstrated in this paper\",\n      \"pmids\": [\"10198171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CDC42BPB (MRCKβ) functions as a downstream effector of CDC42 in epithelial cells, where it participates in apical membrane morphogenesis, lumen formation, and junction maturation by coordinating cytoskeleton regulation in response to localized CDC42 activation.\",\n      \"method\": \"Review synthesizing genetic and cell-biological studies in multiple model systems (Drosophila, C. elegans, mammalian epithelial cells)\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — synthesis of multiple experimental studies linking CDC42BPB to CDC42 effector function in epithelial polarity; not a single direct experiment but draws on established genetic epistasis and loss-of-function data across labs\",\n      \"pmids\": [\"31113848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CDC42BPB kinase activity regulates cation-independent mannose 6-phosphate receptor (CI-M6PR) trafficking in HeLa cells; siRNA knockdown of CDC42BPB was identified in a visual screen as perturbing CI-M6PR membrane trafficking pathways.\",\n      \"method\": \"High-throughput fluorescence imaging screen using kinase siRNA library and kinase inhibitors in HeLa cells\",\n      \"journal\": \"Genes to cells\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, high-throughput screen without mechanistic follow-up on CDC42BPB specifically; no direct biochemical validation of the trafficking phenotype\",\n      \"pmids\": [\"19210549\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CDC42BPB (Cdc42bpb) protein is present in the apical plasma membrane of mouse cortical collecting duct cells and undergoes significant abundance changes in response to vasopressin, implicating it as a signal-induced regulator of F-actin dynamics in this context.\",\n      \"method\": \"Stable isotope-based quantitative protein mass spectrometry combined with surface biotinylation of apical plasma membrane proteins\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative proteomics with surface biotinylation showing vasopressin-regulated changes in apical membrane abundance; single lab but two orthogonal quantitative methods\",\n      \"pmids\": [\"24085853\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CDC42BPB was identified as a novel putative target kinase of the Akt inhibitor GSK690693, detected by chemical affinity profiling using a synthesized AGC kinase-targeting probe in human cancer cell lysates.\",\n      \"method\": \"Chemical proteomics / kinase affinity profiling using synthesized chemical probe (kinobeads) combined with mass spectrometry in human cancer cells\",\n      \"journal\": \"Journal of proteome research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single chemical proteomics method; putative target identification without direct enzyme inhibition assay or mutagenesis validation\",\n      \"pmids\": [\"23795919\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CDC42BPB (Cdc42bpb) was identified as a protein kinase that physically interacts with the urea channel UT-A1 in native rat inner medullary collecting duct cells, and in vitro incubation experiments showed that Cdc42bpb was capable of phosphorylating known UT-A1 phosphorylation sites.\",\n      \"method\": \"Chemical cross-linking, immunoprecipitation, LC-MS/MS, and in vitro kinase assay using UT-A1 peptides\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP/MS identification of interaction confirmed by in vitro kinase phosphorylation of substrate peptides; single lab, two orthogonal methods\",\n      \"pmids\": [\"29046292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"MRCKβ (CDC42BPB) phosphorylates the E3 ubiquitin ligase Siah2 at Ser6 and Thr279 in H. pylori-infected gastric epithelial cells. This phosphorylation stabilizes Siah2 and promotes its tumorigenic functions; in turn, Siah2 ubiquitinates MRCKβ leading to its proteasomal degradation. Phosphorylation-null Siah2 mutants (S6A and T279A) showed reduced tumorigenicity.\",\n      \"method\": \"Co-immunoprecipitation followed by mass spectrometry to identify kinase, site-directed mutagenesis of Siah2 phosphorylation sites, western blotting, proteasome inhibitor rescue (MG132), clonogenicity, proliferation, invasion, and anchorage-independent growth assays\",\n      \"journal\": \"Journal of biomedical science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — Co-IP/MS identification of kinase, mutagenesis of substrate phosphorylation sites with functional phenotypic validation (tumorigenicity assays), proteasomal rescue experiment; multiple orthogonal methods in single lab\",\n      \"pmids\": [\"33536006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Heterozygous predicted loss-of-function variants in CDC42BPB (frameshift and nonsense), expected to cause haploinsufficiency via nonsense-mediated decay, and missense variants in functionally important protein domains (kinase domain, citron homology domain, coiled-coil regions) are associated with neurodevelopmental disorders including developmental delay, intellectual disability, autism, and structural brain abnormalities. Variants were confirmed de novo in 11/14 individuals.\",\n      \"method\": \"Whole-exome/genome sequencing with de novo variant confirmation in 14 unrelated individuals; in silico domain mapping of missense variants\",\n      \"journal\": \"American journal of medical genetics. Part A\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — human genetic evidence across 14 unrelated individuals with de novo confirmation; domain localization provides functional inference but no direct biochemical assay of variant effects\",\n      \"pmids\": [\"32031333\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CDC42BPB kinase phosphorylates AURKA, which in turn upregulates PD-L1 through cMYC in breast cancer cells. CRISPR-Cas9 kinome knockout of CDC42BPB and pharmacological inhibition with BDP5290 synergized with anti-PD-1 to enhance T cell-mediated tumor killing. Anti-PD-1-resistant breast cancer cells showed higher CDC42BPB expression, and its inhibition restored susceptibility to T cell killing.\",\n      \"method\": \"CRISPR-Cas9 kinome knockout library screen, pharmacological inhibition (BDP5290), in vitro T cell killing assay, in vivo mouse tumor models, mechanistic analysis of AURKA-cMYC-PD-L1 axis\",\n      \"journal\": \"Molecular therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR screen combined with pharmacological inhibition and in vitro/in vivo validation; AURKA phosphorylation by CDC42BPB stated but the abstract does not detail direct biochemical phosphorylation assay; single lab\",\n      \"pmids\": [\"39086134\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"Loss of Cdc42bpb in mice leads to ventral diaphragmatic hernias, heart septal defects, and minor lung epithelial differentiation defects in embryos. Installation of a patient-specific missense variant via CRISPR/Cas9 knock-in resulted in less severe ventral diaphragm defects, establishing CDC42BPB as a genetic cause of congenital diaphragmatic hernia.\",\n      \"method\": \"Mouse knockout (loss-of-function) and CRISPR/Cas9 patient-variant knock-in; embryonic phenotyping for diaphragm, heart, and lung defects\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo loss-of-function with specific anatomical phenotypic readouts and patient-variant knock-in; preprint, single lab, not yet peer-reviewed\",\n      \"pmids\": [\"42124667\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Heterozygous deletion of Cdc42bpb in mice (Cdc42bpb +/-) did not produce significant differences from wild-type littermates in alcohol-related behavioral tests (loss of righting reflex, light-dark box, two-bottle choice drinking), though mild hyperactivity and some urogenital deformities were observed.\",\n      \"method\": \"Behavioral battery testing in heterozygous Cdc42bpb knockout mice\",\n      \"journal\": \"microPublication biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct in vivo loss-of-function experiment with specific behavioral readouts; negative result for alcohol behaviors is informative; single lab, single method\",\n      \"pmids\": [\"35622514\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CDC42BPB (MRCKβ) is a serine/threonine protein kinase and downstream effector of CDC42 that phosphorylates nonmuscle myosin light chain to activate actin-myosin contractility, phosphorylates Siah2 (promoting its stability while triggering its own proteasomal degradation via Siah2-mediated ubiquitination), and phosphorylates AURKA to upregulate PD-L1 via cMYC; it regulates actin cytoskeleton dynamics, epithelial polarity, membrane trafficking, and vasopressin-regulated actin remodeling in renal collecting duct cells, and is required for normal diaphragm and heart development in vivo, with loss-of-function and dominant missense variants causing neurodevelopmental disorders and congenital diaphragmatic hernia in humans and mice.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CDC42BPB (MRCKβ) is a broadly expressed serine/threonine protein kinase that acts as a downstream effector of CDC42 to regulate the actin cytoskeleton, epithelial polarity, and membrane morphogenesis [#0, #1]. Through phosphorylation of nonmuscle myosin light chain it links CDC42 activation to actin-myosin contractility, and in epithelial cells it coordinates apical membrane morphogenesis, lumen formation, and junction maturation in response to localized CDC42 signaling [#0, #1]. In the renal collecting duct, the kinase localizes to the apical plasma membrane where its abundance changes upon vasopressin stimulation, and it interacts with and phosphorylates the urea channel UT-A1, implicating it in signal-induced F-actin and membrane-transport regulation [#3, #5]. CDC42BPB also has substrate roles in disease contexts: it phosphorylates the E3 ligase Siah2 at Ser6/Thr279 to stabilize Siah2 and promote tumorigenicity, while Siah2 reciprocally ubiquitinates MRCKβ to drive its proteasomal degradation [#6], and it phosphorylates AURKA to upregulate PD-L1 via cMYC, with its loss or inhibition restoring tumor susceptibility to T cell killing [#8]. In vivo, loss of Cdc42bpb in mice produces ventral diaphragmatic hernias and heart septal defects, establishing the gene as a genetic cause of congenital diaphragmatic hernia [#9]. Heterozygous loss-of-function and de novo missense variants in the kinase, citron homology, and coiled-coil domains cause neurodevelopmental disorders including developmental delay, intellectual disability, and autism [#7].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established the molecular identity and core enzymatic activity of the human gene by cloning it as a serine/threonine kinase acting on nonmuscle myosin light chain.\",\n      \"evidence\": \"cDNA cloning, Northern blot, and FISH mapping of the human MRCKβ homologue\",\n      \"pmids\": [\"10198171\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Myosin light chain phosphorylation inferred from rat ortholog, not directly re-demonstrated\", \"No structural or substrate-site characterization in human protein\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Addressed whether the kinase participates in intracellular trafficking by implicating it in mannose-6-phosphate receptor membrane transport.\",\n      \"evidence\": \"High-throughput kinase siRNA/inhibitor fluorescence imaging screen of CI-M6PR trafficking in HeLa cells\",\n      \"pmids\": [\"19210549\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Screen hit without mechanistic follow-up specific to CDC42BPB\", \"No biochemical validation of the trafficking phenotype\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Connected the kinase to physiological signaling by showing its apical membrane abundance in collecting duct cells changes with vasopressin, suggesting a role in signal-induced actin remodeling.\",\n      \"evidence\": \"Quantitative SILAC mass spectrometry with apical surface biotinylation in mouse cortical collecting duct cells\",\n      \"pmids\": [\"24085853\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Abundance change does not establish a direct kinase substrate in this context\", \"Functional consequence for actin dynamics not directly assayed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified a tissue-specific substrate by showing the kinase binds and phosphorylates the urea channel UT-A1, linking it to renal transport regulation.\",\n      \"evidence\": \"Cross-linking, Co-IP/LC-MS/MS, and in vitro kinase assay on UT-A1 peptides in rat inner medullary collecting duct\",\n      \"pmids\": [\"29046292\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Phosphorylation shown on peptides, not validated on full-length UT-A1 in vivo\", \"Functional effect on channel activity not measured\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established human disease relevance by linking heterozygous loss-of-function and de novo missense variants to neurodevelopmental disorders.\",\n      \"evidence\": \"Whole-exome/genome sequencing of 14 unrelated individuals with de novo confirmation and in silico domain mapping\",\n      \"pmids\": [\"32031333\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct biochemical assay of variant effects on kinase activity\", \"Mechanism connecting haploinsufficiency to brain phenotype unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Revealed a reciprocal kinase-ligase relationship by showing MRCKβ phosphorylates and stabilizes Siah2 while being targeted for degradation by it, defining an oncogenic feedback loop.\",\n      \"evidence\": \"Co-IP/MS, site-directed mutagenesis (S6A/T279A), MG132 rescue, and tumorigenicity assays in H. pylori-infected gastric epithelial cells\",\n      \"pmids\": [\"33536006\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this circuit operates outside gastric cancer not addressed\", \"Upstream signals controlling the loop not defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Connected the kinase to tumor immune evasion by showing it phosphorylates AURKA to upregulate PD-L1 via cMYC and modulate anti-PD-1 response.\",\n      \"evidence\": \"CRISPR-Cas9 kinome screen, BDP5290 inhibition, in vitro T cell killing, and in vivo breast cancer models\",\n      \"pmids\": [\"39086134\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct biochemical AURKA phosphorylation assay not detailed\", \"Generality beyond breast cancer not established\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Established CDC42BPB as a genetic cause of congenital diaphragmatic hernia through in vivo loss-of-function and patient-variant modeling.\",\n      \"evidence\": \"Mouse knockout and CRISPR/Cas9 patient-variant knock-in with embryonic phenotyping of diaphragm, heart, and lung (preprint)\",\n      \"pmids\": [\"42124667\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint, not yet peer-reviewed\", \"Cellular mechanism linking kinase loss to diaphragm defect not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The direct in-cell substrate repertoire that mediates the cytoskeletal, developmental, and disease phenotypes, and how CDC42 activation is mechanistically transduced through MRCKβ in each tissue, remain undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unifying mechanistic link between actin regulation and the diverse disease phenotypes\", \"No structural model of substrate recognition\", \"Variant effects on kinase activity not biochemically tested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 5, 6, 8]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 5, 6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [9]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CDC42\", \"SIAH2\", \"AURKA\", \"UT-A1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":6,"faith_total":6,"faith_pct":100.0}}